+1 201 314 5432

Scientific Advisory Board


Daniel D. Von Hoff, MD, FACP

Daniel D. Von Hoff, MD, FACP is Professor of Medicine at the Mayo Clinic and Chief Development Officer at TD2. He also serves as Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona, as well as Chief Scientific Officer for US Oncology and for Honor Health’s Clinical Research Institute. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, nab-paclitaxel and vismodegib. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 620 papers, 137 book chapters and over 1050 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and former Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Henry Friedman, MD

Ursula A. Matulonis, MD

Ursula A. Matulonis, MD, is Director and Disease Center Leader of the Gynecologic Oncology Program at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer.

Dr. Matulonis has led several PARP inhibitor, anti-angiogenic agent and combination trials for ovarian cancer in the United States. Dr. Matulonis serves on the National Comprehensive Cancer Network Recommendation and Guideline committee for ovarian cancer, the Massachusetts Ovarian Cancer Task Force, the NRG ovarian committee, and the Scientific Advisory Board for the Ovarian Cancer Research Foundation Alliance and the Clearity Foundation. She received the Dennis Thompson Compassionate Care Scholar award, the Lee M. Nadler “Extra Mile” Award, and the Zakim Award for patient advocacy.

After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at the Dana-Farber Cancer Institute in Boston, MA.

Mansoor Raza Mirza, MD

Joyce A. O’Shaughnessy, MD

Joyce A. O’Shaughnessy, MD specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O’Shaughnessy focuses on breast cancer prevention and treatment. She is Co-Chair of Breast Cancer Research and Chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center and for The US Oncology Network and is a member of the Scientific Advisory Board for US Oncology Research Network.

Dr. O’Shaughnessy received her MD from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995.

Dr. O’Shaughnessy is a member of American Association for Cancer Research, American Society of Clinical Oncology, American Medical Women’s Association, American Medical Association, American College of Physicians, and Women in Cancer Research. She is Associate Editor, Clinical Breast Cancer Journal, founder of The School of Breast Oncology. In 2009 D Magazine elected Dr. O’Shaughnessy as one of the best hematology oncologists in Dallas, Texas.

Mary Lake Polan, MD, PhD, MPH

Mary Lake Polan, MD, PhD, MPH, served as the chair of the Department of Obstetrics and Gynecology at the Stanford University School of Medicine from 1990 to 2006 and is currently a Clinical Professor, Department of Obstetrics and Gynecology and Reproductive Sciences at Yale University School of Medicine.

Dr. Polan specializes in reproductive endocrinology and infertility and hormonal issues related to gynecology patients and menopause. She received her bachelor’s degree from Connecticut College and her PhD in Molecular Biophysics and Biochemistry and MD from Yale University and completed her residency and Reproductive Endocrine Fellowship in the Department of Obstetrics and Gynecology at the Yale University School of Medicine. Dr. Polan received her MPH (Maternal and Child Health Program) from the University of California, Berkeley.

Dr. Polan served on the board of Wyeth Pharmaceuticals prior to it’s acquisition by Pfizer and currently serves on the board of Quidel Corp and Motif Biosciences as well as on the boards of several privately held life sciences companies. She chairs an SAB in Women’s Health for the Proctor and Gamble Company and participates in several other advisory boards of private life sciences companies. She is also a Managing Director of Golden Seeds, an angel investing group which invests in women led companies.

Dr. Polan’s research has involved ovarian and urologic function with many publications in both areas. She is a member of the National Academy of Medicine, a part of the National Academy of Sciences and has served on a number of NIH and university committees. She has a long-standing interest in women’s health research and has been actively involved in international public health. While at Stanford Medical School, she initiated The Eritrean Women’s Project in 2001 and has maintained this surgical project in Eritrea to repair fistulas resulting from traumatic births.